

Actinium Pharmaceuticals, Inc.  
275 Madison Avenue, 7<sup>th</sup> Floor  
New York, New York 10016

August 14, 2020

**VIA EDGAR**

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
Securities and Exchange Commission  
Washington, D.C. 20549  
Attention: Laura Crotty

Re: Actinium Pharmaceuticals, Inc.  
Registration Statement on Form S-3  
Filed August 7, 2020  
File No. 333-242322 (the "**Registration Statement**")  
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 of the Rules and Regulations of the Securities and Exchange Commission (the "**Commission**") under the Securities Act of 1933, as amended, Actinium Pharmaceuticals, Inc. hereby respectfully requests acceleration of the effective date of the Registration Statement so that it may become effective at 4:30 p.m., Eastern Time, on August 14, 2020, or as soon thereafter as practicable.

Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Haynes and Boone, LLP, attention: Rick A. Werner, Esq. at (212) 659-4974.

Very truly yours,

ACTINIUM PHARMACEUTICALS, INC.

By: /s/ Steven O'Loughlin  
Steven O'Loughlin  
Chief Financial Officer

cc: Rick A. Werner, Esq., Haynes and Boone, LLP